AKEEGA (niraparib + abiraterone acetate)
AKEEGA combines niraparib with abiraterone acetate and is developed by Johnson & Johnson. It is used in biomarker-informed settings for certain prostate cancer indications.
Where this therapy is approved with a companion diagnostic
Each row represents a defined combination of indication, biomarker criteria, and AKEEGA. Select a testing pathway to see the eligible companion diagnostic tests.
Approvals where AKEEGA is tied to a specific indication and biomarker definition.
| Indication | Biomarker criteria | Notes | |
|---|---|---|---|
Prostate Cancer Solid Tumor · Prostate | BRCA1
| View testing pathway → | |
Metastatic Castrate Resistant Prostate Cancer (mCRPC) Solid Tumor · Prostate | BRCA1
| View testing pathway → |
Approvals defined at the solid tumor level where biomarker criteria determine eligibility for AKEEGA.
No tumor-agnostic companion diagnostic approvals are currently mapped for this therapy.
Tests used in these approvals
These assays are identified in FDA labeling or sponsor materials as companion diagnostics or acceptable tests when considering AKEEGA for eligible patients.